Women's Health & Pregnancy Clinical Trials

Statistical methods in women's health & pregnancy trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All women's health & pregnancy trials

790 results

• EMPOWER-MomIndependent statistical analysis of Postpartum Weight Loss for Women at Elevated Cardiovascular Risk: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04914819).Phase NAResults postedn = 89NCT04914819
• ENDOMEDEIndependent statistical analysis of Clinical Performance and Safety Investigation of ENDOmetrial Washing MEdical DEvice Forielle: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 9NCT03387059
• Endometrial Injury for Unexplained Infertility: Complete Statistical AnalysisIndependent statistical analysis of Endometrial Injury for Unexplained Infertility: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02863198).Phase NAResults postedn = 120NCT02863198
• ENVISIONIndependent statistical analysis of A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 240NCT05243550
• Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 28NCT00407758
• EpHectIndependent statistical analysis of Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 26NCT05507333
• ePHex-OLEIndependent statistical analysis of An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 22NCT03938272
• EPICIndependent statistical analysis of Mechanisms of EPO-induced Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03810911).Phase 2Results postedn = 27NCT03810911
• Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 31NCT00176488
• Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1Results postedn = 27NCT02120469
• Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 86NCT01908101
• Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 74NCT00334893
• Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 52NCT01269346
• Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 39NCT00054275
• ESS-NSPASIndependent statistical analysis of A Study to Evaluate the Effectiveness of Essure Post-NovaSure Radiofrequency Endometrial Ablation Procedure Following a Successful Essure Confirmation Test: primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 211NCT01740687
• ESTEEMIndependent statistical analysis of Combined Treatment for Mixed Incontinence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01959347).Phase 3Results postedn = 480NCT01959347
• Estrogen for Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Estrogen for Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01083641).Phase 2Results postedn = 17NCT01083641
• Estrogen Variability and Irritability During the Menopause Transition: Complete Statistical AnalysisIndependent statistical analysis of Estrogen Variability and Irritability During the Menopause Transition: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05388656).Phase 4Results postedn = 40NCT05388656
• Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation: Complete Statistical AnalysisIndependent statistical analysis of Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02348684).Phase NAResults postedn = 20NCT02348684
• Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression: Complete Statistical AnalysisIndependent statistical analysis of Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 32NCT00944047
• Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria: Complete Statistical AnalysisIndependent statistical analysis of Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 16NCT02289755
• Evaluating Digital Micro-Interventions to Reduce Distress and Increase Wellbeing in Breast Cancer Survivors: Complete Statistical AnalysisIndependent statistical analysis of Evaluating Digital Micro-Interventions to Reduce Distress and Increase Wellbeing in Breast Cancer Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 120NCT07160439
• Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 240NCT04601272
• Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02165761).Phase NAResults postedn = 42NCT02165761
• Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1Results postedn = 603NCT00050167
• Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 4Results postedn = 873NCT01031069
• Evaluation of the Accuracy and Usability of the ACR | U.S. Urine Analysis Test System in the Lay User Hands: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the Accuracy and Usability of the ACR | U.S. Urine Analysis Test System in the Lay User Hands: primary endpoint results, effect estimate with confidence interval,…Phase NAResults postedn = 250NCT04626271
• Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 217NCT03317444
• Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 48NCT02291913
• EVIDENCEIndependent statistical analysis of Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment: primary endpoint results, effect estimate with confidence interval,…Phase NAResults postedn = 67NCT02614898
• Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00810797).Phase 2Results postedn = 36NCT00810797
• Exercise Training and Cognitive Function in Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Exercise Training and Cognitive Function in Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03197038).Phase NAResults postedn = 39NCT03197038
• Exploring Life Experience and Lifestyle Intervention Program Among Patients With CKD: Complete Statistical AnalysisIndependent statistical analysis of Exploring Life Experience and Lifestyle Intervention Program Among Patients With CKD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 120NCT01194518
• Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 276NCT04103450
• F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 20NCT00602043
• FACTComplete statistical analysis of the FACT phase 3 trial of high-dose folic acid supplementation throughout pregnancy for preeclampsia prevention, including randomized trial design, endpoint definitions, risk ratios, confidence intervals, missing-data considerations, and…Phase 3Results postedn = 2,464NCT01355159
• FAVORITComplete statistical analysis of FAVORIT, a randomized phase 2/3 trial evaluating high-dose versus low-dose multivitamins in kidney transplant recipients with cardiovascular disease risk.Phase 2/3Results postedn = 4,110NCT00064753
• Feasibility of “At-home” Titration of Solifenacin: Complete Statistical AnalysisIndependent statistical analysis of Feasibility of "At-home" Titration of Solifenacin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00759577).Phase 4Results postedn = 36NCT00759577
• Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 15NCT01045187
• Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 21NCT00582205
• Fecal Microbiota Transplantation (FMT) for MDRO UTI: Complete Statistical AnalysisIndependent statistical analysis of Fecal Microbiota Transplantation (FMT) for MDRO UTI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03367910).Phase 1/2Results postedn = 1NCT03367910
• Fetal Tracheal Balloon Study in Diaphragmatic Hernia: Complete Statistical AnalysisIndependent statistical analysis of Fetal Tracheal Balloon Study in Diaphragmatic Hernia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00966823).Phase 2Results postedn = 3NCT00966823
• FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03212170).Phase 2Results postedn = 21NCT03212170
• FIDELIO-DKDIndependent statistical analysis of Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 5,734NCT02540993
• FIGARO-DKDIndependent statistical analysis of FIGARO-DKD, a randomized phase 3 trial of finerenone versus placebo in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.Phase 3Results postedn = 7,352NCT02545049
• Financial Incentives for Smoking Cessation Among Disadvantaged Pregnant Women: Complete Statistical AnalysisIndependent statistical analysis of Financial Incentives for Smoking Cessation Among Disadvantaged Pregnant Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02210832).Phase NAResults postedn = 257NCT02210832
• First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study: Complete Statistical AnalysisIndependent statistical analysis of First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study: primary endpoint…Phase 4Results postedn = 458NCT01419249
• Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2/3Results postedn = 2NCT01259284
• Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896): Complete Statistical AnalysisIndependent statistical analysis of Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 306NCT01190254
• Fluid Chloride and AKI in Cardiopulmonary Bypass: Complete Statistical AnalysisIndependent statistical analysis of Fluid Chloride and AKI in Cardiopulmonary Bypass: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02668952).Phase 2Results postedn = 30NCT02668952

← All therapeutic areas